Generate Biomedicines, Inc. (GENB) Key Metrics
GENB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.55B
- Enterprise value
- $1.73B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 58.6
- Price / book
- 4.6
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
GENB key metrics, 2024–2025
Fiscal year ended December 31, 2025 · U.S. dollarsGENB returns How much profit the business earns on the capital it uses.
GENB per-share figures Results divided by the shares outstanding at year-end.
GENB financial health Debt, liquidity and how easily interest is covered.
GENB efficiency & capital use Working capital cycle and where the cash goes.
GENB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GENB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GENB key metrics
2024–2025| 2025 | 2024 | |
|---|---|---|
| Per share | ||
| Revenue per share | $0.64 | $0.16 |
| Earnings per share | −$4.06 | −$1.36 |
| Operating cash flow per share | −$4.01 | −$0.92 |
| Free cash flow per share | −$4.08 | −$0.95 |
| Cash per share | $4.42 | $3.09 |
| Book value per share | −$12.30 | −$3.41 |
| Tangible book value per share | −$12.30 | −$3.41 |
| Capex per share | $0.07 | $0.03 |
| Debt per share | $1.37 | $0.60 |
| Shares outstanding | 50.1M | 127.5M |
| Change in shares outstanding | −60.7% | — |
| Returns & profitability | ||
| Return on assets (ROA) | −47.9% | −33.5% |
| Return on tangible assets | −61.5% | −33.5% |
| Free cash flow margin | −640.1% | −592.4% |
| Financial health | ||
| Total debt | $68.5M | $77.0M |
| Cash & short-term investments | $221.5M | $393.6M |
| Net debt | −$153.0M | −$316.7M |
| Debt / assets | 0.21 | 0.15 |
| Current ratio | 2.85 | 4.70 |
| Quick ratio | 2.85 | 4.70 |
| Interest coverage | -206.9 | -93.0 |
| Working capital | $152.2M | $320.9M |
| Invested capital | −$768.9M | −$751.2M |
| Tangible asset value | −$623.2M | −$435.1M |
| Net current asset value | −$719.0M | −$545.9M |
| Graham net-net per share | −$14.61 | −$4.39 |
| Capital allocation | ||
| Capex / revenue | 11.0% | 16.8% |
| Capex / depreciation | 0.27 | 0.22 |
| Stock-based compensation / revenue | 64.5% | 95.1% |
| R&D / revenue | 704.5% | 856.9% |
| SG&A / revenue | 132.5% | 205.7% |
| Efficiency | ||
| Days sales outstanding | 1.8 | 5.5 |
| Receivables turnover | 207.10 | 66.43 |
| Payables turnover | 0.00 | 0.00 |
| Asset turnover | 0.08 | 0.04 |
| Average receivables | $154,000 | $308,000 |
| Average payables | $4.8M | $5.7M |
| Intangibles / total assets | 0.0% | 0.0% |
Computed from GENB's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
GENB valuation and financial ratios
It ended the year with $68.5 million of debt and $221.5 million in cash and short-term investments, a net cash position of $153.0 million.
See the GENB income statement, the GENB chart for price history, or the GENB stock overview for the latest quote and news.
GENB key metrics FAQ
How much debt does Generate Biomedicines have?
Generate Biomedicines had total debt of $68.5 million at the end of fiscal 2025 and more cash than debt.
What is Generate Biomedicines's current ratio?
Generate Biomedicines's current ratio was 2.85 at the end of fiscal 2025: current assets were 2.85 times current liabilities.